CC-90009:靶向急性髓系白血病原始细胞与白血病干细胞的GSPT1选择性cereblon调节剂
CC-90009是一种首创的GSPT1选择性cereblon E3连接酶调节剂,通过CRL4CRBN复合物选择性泛素化并降解GSPT1,快速诱导AML凋亡并减少35例原代患者异种移植中的白血病植入和白血病干细胞。全基因组CRISPR-Cas9筛选揭示ILF2/ILF3复合物调节cereblon表达,mTOR信号和整合应激反应特异性调控CC-90009应答。
要点
- CC-90009选择性降解GSPT1并诱导AML原始细胞和白血病干细胞凋亡。
- ILF2/ILF3通过调节CRBN mRNA可变剪接影响cereblon表达和CC-90009应答。
- mTOR通路失活保护、GSPT1降解激活GCN1/GCN2/ATF4通路促进凋亡。
核心结论
- CC-90009通过CRL4CRBN选择性靶向GSPT1降解,快速诱导AML凋亡并减少白血病干细胞,其活性受多层信号网络调控。
研究设计与样本
- 临床前研究,包含生化、结构和分子表征,以及35例独立AML患者样本的大规模原代异种移植。
- 全基因组CRISPR-Cas9筛选用于鉴定CC-90009应答效应因子。
- 相关试验注册号为NCT02848001和NCT04336982。
主要发现
- CC-90009利用CRL4CRBN选择性泛素化GSPT1并致其蛋白酶体降解。
- 在35例独立AML样本(包括不良风险特征者)的原代异种移植中,CC-90009减少白血病植入和白血病干细胞。
- ILF2/ILF3异二聚体复合物通过调节CRBN mRNA可变剪接影响全长cereblon蛋白产生,敲除后降低对CC-90009的应答。
- mTOR信号和整合应激反应特异性调控CC-90009应答;TSC1/TSC2失活导致mTOR通路过度激活,减少CC-90009诱导的GSPT1与cereblon结合及后续GSPT1降解,从而保护免受生长抑制。
- GSPT1降解促进GCN1/GCN2/ATF4通路激活及AML细胞凋亡。
临床怎么用
- CC-90009作为GSPT1选择性cereblon调节剂,为AML(包括不良风险特征)提供潜在治疗策略。
- ILF2/ILF3状态和mTOR通路激活可能影响CC-90009疗效,需进一步临床评估。
局限性
- 研究为临床前体外和异种移植模型,尚未报告临床疗效数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
A number of clinically validated drugs have been developed by repurposing the CUL4-DDB1-CRBN-RBX1 (CRL4CRBN) E3 ubiquitin ligase complex with molecular glue degraders to eliminate disease-driving proteins. Here, we present the identification of a first-in-class GSPT1-selective cereblon E3 ligase modulator, CC-90009. Biochemical, structural, and molecular characterization demonstrates that CC-90009 coopts the CRL4CRBN to selectively target GSPT1 for ubiquitination and proteasomal degradation. Depletion of GSPT1 by CC-90009 rapidly induces acute myeloid leukemia (AML) apoptosis, reducing leukemia engraftment and leukemia stem cells (LSCs) in large-scale primary patient xenografting of 35 independent AML samples, including those with adverse risk features. Using a genome-wide CRISPR-Cas9 screen for effectors of CC-90009 response, we uncovered the ILF2 and ILF3 heterodimeric complex as a novel regulator of cereblon expression. Knockout of ILF2/ILF3 decreases the production of full-length cereblon protein via modulating CRBN messenger RNA alternative splicing, leading to diminished response to CC-90009. The screen also revealed that the mTOR signaling and the integrated stress response specifically regulate the response to CC-90009 in contrast to other cereblon modulators. Hyperactivation of the mTOR pathway by inactivation of TSC1 and TSC2 protected against the growth inhibitory effect of CC-90009 by reducing CC-90009-induced binding of GSPT1 to cereblon and subsequent GSPT1 degradation. On the other hand, GSPT1 degradation promoted the activation of the GCN1/GCN2/ATF4 pathway and subsequent apoptosis in AML cells. Collectively, CC-90009 activity is mediated by multiple layers of signaling networks and pathways within AML blasts and LSCs, whose elucidation gives insight into further assessment of CC-90009s clinical utility. These trials were registered at www.clinicaltrials.gov as #NCT02848001 and #NCT04336982).
引用
- Surka C, Jin L, Mbong N, et al. CC-90009, a novel cereblon E3 ligase modulator, targets acute myeloid leukemia blasts and leukemia stem cells. Blood. 2021. PMID: 33197925. doi:10.1182/blood.2020008676
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。